I think of C-TAP, which isn't being used, but there are structures there to pool resources and know-how. The waiver provides a will to do so and a global commitment to do so. The pharmaceutical companies could be doing voluntary licensing right now, but there is no push or consensus by the WTO to make that happen. C-TAP is one example of how that could play out.
On April 23rd, 2021. See this statement in context.